| Hazard Information | Back Directory | [Uses]
Iscalimab (CFZ-533) is a non-depleting IGg1 monoclonal antibody targeting CD40 (KD: 0.3 nM). Iscalimab can be used for research of Graves' hyperthyroidism and autoimmune diseases[1][2][3]. | [in vivo]
Iscalimab (150 mg/kg/week, s.c, for 13 weeks) is well tolerated and does not cause any dose-limiting toxicity in rhesus monkeys[3].
Iscalimab (10 mg/kg, i.v.) completely inhibits T cell-dependent antibody response in Rhesus monkeys[3].
Iscalimab (30 mg/kg, i.v.) prolongs allograft survival in kidney transplant cynomolgus[4].
| Animal Model: | Kidney transplant cynomolgus[4] | | Dosage: | 30 mg/kg | | Administration: | i.v. | | Result: | Prolonged allograft survival.
Well-tolerated with no evidence of thromboembolic events or CD40 pathway activation.
|
| [IC 50]
CD40: 0.3 nM (IC50) | [References]
[1] Kahaly GJ, et al. A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism-A Proof-of-Concept Trial. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgz013. DOI:10.1210/clinem/dgz013
[2] Flandre TD, et al. Immunosuppression Profile of CFZ533 (Iscalimab), a Non-Depleting Anti-CD40 Antibody, and the Presence of Opportunistic Infections in a Rhesus Monkey Toxicology Study. Toxicol Pathol. 2022 Jul;50(5):712-724. DOI:10.1177/01926233221100168
[3] Ristov J, et al. Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody. Am J Transplant. 2018 Dec;18(12):2895-2904. DOI:10.1111/ajt.14872
[4] Cordoba F, et al. A novel, blocking, Fc-silent anti-CD40 monoclonal antibody prolongs nonhuman primate renal allograft survival in the absence of B cell depletion. Am J Transplant. 2015 Nov;15(11):2825-36. DOI:10.1111/ajt.13377 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|